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To develop novel and more potent quinazoline–phosphoramidate mustard conjugates as epidermal growth factor
receptor (EGFR) inhibitor, three-dimensional quantitative structure-activity relationship [comparative molecular
field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA)] combined with molecular
docking were performed. A series of 13 compounds in the training set gave q2 values of 0.577 and 0.537, as well as r2
values of 0.926 and 0.921 for CoMFA and CoMSIA models, respectively. The contour maps that were produced by the
CoMFA and CoMSIA models revealed that steric, electrostatic, and hydrophobic fields were crucial in the inhibitory
activity of quinazoline–phosphoramidate derivatives. Based on the CoMFA and CoMSIA models, several novel EGFR
inhibitors were designed, which established crucial interactions at the ligand binding domain of EGFR. Nearly, 100
ns MD simulation indicated the stability of the designed compounds at 100 ns, while molecular mechanics-Poisson
Boltzmann surface area calculation showed that the designed compound had a higher affinity than that of the parent
compound.

Key words:
3D-QSAR, CoMFA,
CoMSIA, docking,
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INTRODUCTION
The non-small cell lung cancer (NSCLC) represents
the most prevalent lung cancer worldwide with less than 20%
of 5-year survival rate after diagnosis (Chen et al., 2018; Gaber
et al., 2018; Hao et al., 2018). The epidermal growth factor
receptor (EGFR) is a member of the protein kinase family,
which is a clinically validated target for NSCLC treatment.
EGFR is involved in various cellular signaling cascades, which
are crucial in cell growth, proliferation, survival, and migration.
Due to its crucial role, there have been continuous efforts to find
a small molecule that is able to inhibit EGFR, particularly for
the NSCLC treatment. Erlotinib and Gefitinib were considered
as the first-generation of EGFR inhibitors, which were used for
the treatment of NSCLC (Bonomi, 2003; Vansteenkiste, 2004).
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However, it was known that the T790M point mutation in the
EGFR, which was the substitution of Thr790 with Met residue,
had induced acquired resistance after a median of 10–14 months
to most NSCLC patients of first-generation EGFR inhibitors
(Kobayashi et al., 2005). Furthermore, Afatinib and canertinib
(Ou, 2012), two of several second-generation EGFR inhibitors,
were approved by FDA for the treatment of metastatic NSCLC
patients. However, the nonselective inhibition against wild type of
EGFR has limitations in their clinical use (Gaber et al., 2018). The
third-generation EGFR inhibitors such as rociletinib and avitinib
(Walter et al., 2013) were developed; however, it was reported
that the hyperglycemia was observed in NSCLC patients who used
Rociletinib (Chen et al., 2018; Yver, 2016).
Lin et al. (2017) designed and synthesized a series of
phosphoramide mustard functionality, which was incorporated
into the quinazoline scaffold, and their potential as EGFR
inhibitors for the treatment of lung cancer was investigated. It
was found that the designed compound could inhibit EGFR with
IC50 at the nanomolar range and showed no acute toxicity to
mice at a single dose up to 900 mg/kg. It was concluded that the

© 2019 Ruslin Ruslin et al. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License
(https://creativecommons.org/licenses/by/4.0/).
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designed compound posed a potential as EGFR inhibitor. Based
on these results, the present study was aimed to build a model
of three-dimensional quantitative structure-activity relationship
(3D-QSAR) including comparative molecular field analysis
(CoMFA) (Cramer et al., 1988) and comparative molecular
similarity indices analysis (CoMSIA) (Klebe et al., 1994) of
quinazoline–phosphoramidate mustard conjugates. Using the
built model, a novel compound was proposed, and molecular
docking and molecular dynamics simulation were then used
to check the conformational stability of the newly proposed
compound in the binding site of EGFR.

MATERIALS AND METHODS
17 compounds of quinazoline–phosphoramidate mustard
conjugates were selected based on the literature study (Lin et al.,
2017). Based on a random selection, the compounds were grouped
into a training set (13 compounds) and a test set (four compounds)
(Table 1) by considering structural diversity and distribution of
biological data. The inhibitory activity [IC50 (nM)] values were
converted to the logarithmic scale (pIC50), where pIC50 = −Log
IC50 (Table 2). The training set was used to develop 3D-QSAR,
including CoMFA and CoMSIA, while the test set was used to
evaluate the model’s validity. All structure sketching, optimization,
and modeling were conducted with SYBYL-2.1 program package
(Tripos, Inc.).

Minimization and alignment
Each compound was sketched and energy-minimized
using Tripos molecular mechanic force field and Powell
method (Clark et al., 1989), while charges were assigned using
Gasteiger–Huckel method (Purcell and Singer, 1967) in the
SYBYL-X 2.1. The minimization was conducted using energy
convergence threshold and maximum iterations of 0.5 kcal/mol
and 1,000 cycles, respectively. Superpositioning of ligands was
conducted based on the core structure, N-phenylquinolin-4amine, by employing compound 12 as a template, since it was
the most active compound. Figure 1 depicts the superimposed
structures of aligned molecules.
CoMFA and CoMSIA
Both CoMFA and CoMSIA were developed employing
SYBYL-X 2.1 (Tripos, Inc., USA). CoMFA steric field was
developed based on van der Waals interaction using LennardJones potential, while CoMFA electrostatic field was based on
Coulombic potential. Both CoMFA fields were generated at each
lattice point of a grid box of 2.0 Å. Cut-off values of 30 kcal/
mol were set for both steric and electrostatic fields (Ståhle and
Wold, 1988).
In CoMSIA, a distance-dependence Gaussian-type
of the physicochemical property has been adopted to avoid any
singularities at the atomic position (Klebe et al., 1994). Similar

Table 1. Chemical structure of quinazoline–phosphoramidate mustard conjugates and their inhibitory activities.

Comp

Substituent

pIC50

R1

R2

n

X

1*/10a

H

3-Br

0

Single bond

8.0362

2/10b

H

3-Br

2

O

8.3665

3/10c

H

3-Br

3

O

8.5229

4/10d

H

3-Br

4

O

8.1308

5*/10e

H

3-Br

5

O

8.6383

6*/10f

H

3-C≡C

4

O

7.9586

7/10g

H

3-Cl-4-F

4

O

8.2218

8/10h

H

3-Cl-4-[(3-F-benzyl)oxo]phenyl

4

O

7.5686

9/10i

H

3-C≡C

3

O

8.1427

10/10j

H

3-Cl-4-F

3

O

8.2441

11*/10k

H

3-Cl-4-[(3-F-benzyl)oxo]phenyl

3

O

7.1249
9.5229

12/10l

OMe

3-Br

3

O

13/10m

OMe

3-Cl-4-F

3

O

9.301

14/10n

OMe

3-Cl-4-[(3-F-benzyl)oxo]phenyl

3

O

7.6576

15/10o

H

3-Br

3

CONH

8.4815

16/10p

H

3-Cl-4-F

3

CONH

8.0605

17/10q

H

3-Cl-4-[(3-F-benzyl)oxo]phenyl

3

CONH

7.585

*Test set.
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Table 2. The observed pIC50s and predicted pIC50s of the training and test set molecules.
Comp

Actual pIC50 (nM)

1*

Predicted pIC50 (nM)
CoMFA

Residual

CoMSIA

Residual

8.0362

8.3865

−0.3503

8.3710

−0.3348

2

8.3665

8.4324

−0.0659

8.5155

−0.1490

3

8.5229

8.506

0.01690

8.4959

0.0270
0.0149

4

8.1308

8.1592

−0.0284

8.1159

5*

8.6383

8.6469

−0.0086

8.4700

0.1683

6*

7.9586

8.2951

−0.3365

8.0713

−0.1127

7

8.2218

8.1785

0.0433

8.1626

0.0592

8

7.5686

7.5567

0.0119

7.5942

−0.0256

9

8.1427

7.9883

0.1544

7.9287

0.2140

10

8.2441

8.3451

−0.1010

8.4419

−0.1978

11*

7.1249

7.5780

−0.4531

7.5708

−0.4459

12

9.5229

9.5269

−0.0040

9.4847

0.0382

13

9.3010

9.2933

0.0077

9.2592

0.0418

14

7.6576

7.6575

0.0001

7.6443

0.0133

15

8.4815

8.3488

0.1327

8.3475

0.1340

16

8.0605

8.1586

−0.0981

8.1859

−0.1254

17

7.5850

7.6546

−0.0696

7.6296

−0.0446

*Test set molecules.

Figure 1. 3D-QSAR structure superposition and alignment of the training set (left) and common substructure used for alignment (right).

standard parameters and no arbitrary cutoff limits constructed for
CoMFA field calculation were used for the calculation of CoMSIA
field including steric (S), electrostatic (E), hydrophobic effects
(H), and hydrogen bond donor (HBD) (D) and hydrogen bond
acceptor (HBA) (A).
The partial least squares method with leave-one-out
cross-validation was employed to correlate the CoMFA electrostatic
and steric fields and CoMSIA electrostatic, steric, HBD, HBA, and
hydrophobic properties, each with EGFR inhibitory activity (Bush
Bruce and Nachbar, 1993). The value of filtering (σ) column was
set to lower than 2.0 kcal/mol to improve the signal-to-noise ratio.
The optimal number of principal component (ONC) was obtained
by applying LOO cross-validation, which was then utilized to
derive the final CoMFA and CoMSIA models. The following

equation was utilized to calculate the cross-validation coefficient
of q2 value:
∑( y − ŷ)2
q2 = 1–
∑( y − ȳ)2
Where y and ŷ are observed and predicted activities of
compound i, respectively, and ȳ is the average observed activity
of the compound in the training set. The best QSAR model was
justified on the basis of high q2, conventional correlation coefficient
R2 values (q2 > 0.50 and R2 > 0.60), low standard error estimation
(SEE), and an optimal number of component values.
Molecular docking
The Surflex-Dock module in SYBYL was utilized to
perform molecular docking to clarify the binding mode of the
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compounds. The X-ray crystal structure of EGFR that was cocrystallized with Erlotinib (PDB entry code: 1M17, resolution:
2.6 Å) was taken from the RCSB Protein Data Bank. The protein
structure was prepared by removing water molecules and cognate
ligand and adding polar hydrogen atoms. Protomol was generated
based on ligand mode, which represented a three-dimensional
space in which ligand make potential interaction with every
binding site.
Automatic docking was applied for molecular docking.
Other parameters were left at default. Total-score of SurflexDock, which was expressed in the negative logarithm of the
dissociation constant, –log10 (Kd), was used to represent binding
affinities. The docked conformation of the ligand was generated
after docking, where those with the highest scores were selected
as the docking results. Each compound was energetically
minimized using the Tripos force field and the Powell algorithm
with a convergence criterion of 0.05 kcal/mol A˚ and Gasteiger–
Huckel charges.
Molecular dynamics simulation and MM-PBSA calculation
Molecular dynamics (MD) simulation of 100 ns was
performed for Compound 12 (Comp12), RA1, RA2, RA3, and
RA4, each complexed with EGFR. The details of MD protocol
follow our previous work (Arba et al., 2018a). Molecular
mechanics-Poisson Boltzmann Surface Area (MM-PBSA)
(Kollman et al., 2000) calculation was performed to predict the
binding free energy of Comp12, RA1, RA2, RA3 and RA4 to
EGFR. The MM-PBSA calculation was performed using 1,500
snapshots taken from 85 to 100 ns. Details of MM-PBSA protocol
were explained in Kollman et al. (2000), Arba et al. (2018b) and
Arba et al. (2018c).

coefficient r2pred = 0.926, which indicated the predictive ability of
the model. Table 2 shows the actual and predicted pIC50 as well as
the residuals of the training and test set compounds, while Table 3
shows the statistical parameters associated with the CoMFA model.
The steric and electrostatic field contributions were found to be
37.4:62.6, which indicated the significant contributions of both
fields on ligand-receptor interaction.
CoMSIA model
Compared to CoMFA, CoMSIA defines five interaction
fields, i.e., steric, electrostatic, hydrophobic, HBD, and HBA.
The final CoMSIA model gave cross-validated correlation
coefficient q2 = 0.537, r2 =0.964, and SEE=0.13 for three
numbers of component. The external validation of the test set
resulted in r2pred = 0.921, which indicated the predictive ability
of the CoMSIA model. The field contribution values for steric,
electrostatic, hydrophobic, HBD, and HBA were 8.6%, 31.7%,
20.7%, 21.2%, and 17.8%, respectively. Figure 2 exhibits the
relationship between the data of predicted and observed activity
for CoMFA and CoMSIA models.

Table 3. PLS statistics of CoMFA and CoMSIA models.

RESULTS AND DISCUSSION
CoMFA model
The quinazoline–phosphoramidate mustard conjugates
were utilized to conduct the CoMFA study. The CoMFA model
calculated from the training set exhibited good cross-validated
correlation coefficient with q2 = 0.577, r2 = 0.982, F = 166.591,
and SEE = 0.09, with three ONC. The external validation of the
CoMFA model using the test set showed good predicted correlation

Statistical parameter

CoMFA

CoMSIA

q2

0.577

0.537

r2

0.982

0.964

rpred

0.926

0.921

F

166.591

62.404

SEE

0.0904529

0.129642

N

3

3

Fraction

CoMFA

CoMSIA

Steric

0.374

0.086

Electrostatic

0.626

0.317

Hydrophobic

-

0.207

Hbond donor

-

0.212

Hbond acceptor

-

0.178

Q = cross-validated correlation coefficient, N = optimum number of components, R2 =
non-cross-validated correlation coefficient, r2ext = external validation correlation coefficient,
SEE = standard error of the estimate, F = F-test value.
2

Figure 2. Scatter plot diagram between actual pIC50 versus predicted pIC50 for (a) CoMFA and (b) CoMSIA.

Ruslin et al. / Journal of Applied Pharmaceutical Science 9 (01); 2019: 089-097

Graphical interpretation of CoMFA and CoMSIA
CoMFA and CoMSIA contour maps were generated
to rationalize the regions in 3D space around the molecules
for increasing the inhibitory activity. The CoMFA steric and
electrostatic contour maps are shown in Figure 3, while the
corresponding CoMSIA contour maps are shown in Figure 4. The
most active compound 12 was used as the reference structure.
CoMFA contour maps
CoMFA steric interactions are represented by green and
yellow colored contours, while CoMFA electrostatic interactions are
shown with red and blue colored contours. The bulky substituents
are favorable in the green regions of steric contours for enhancing
the inhibitory activity, while those in yellow regions may lead to
a decrease in inhibitory activity. Meanwhile, in the map of the
electrostatic field, the blue contours indicate that electropositive
charges are favored for inhibitory activity, while the red contour
designates an increase in inhibitory activity of the electronegative
charges. Compound 12 (Comp12) was utilized to explain the
contour map. Figure 3 exhibits CoMFA steric and electrostatic
contour maps. The steric field contour shows that the small-sized
green contour could be observed near R1 position, which indicates
that the addition of small bulky groups near those green regions
would increase the inhibitory activity. On the other hand, the yellow
contour around the R2 position indicates that hydrophobic or bulky
group substitution near the yellow regions is favored for increasing
the activity. The CoMFA steric interaction agrees well with the
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experimental results. For instance, compound 11 {R1 = H, R2 = 3-Cl4-[(3-F-benzyl)oxo]phenyl, n = 3, X = O}, compound 8 {R1 = H, R2
= 3-Cl-4-[(3-F-benzyl)oxo]phenyl, n = 4, X = O}, compound 17 {R1
= H, R2 = 3-Cl-4-[(3-F-benzyl)oxo]phenyl, n = 3, X = CONH}, and
compound 14 {R1 = OMe, R2 = 3-Cl-4-[(3-F-benzyl)oxo]phenyl, n
= 3, X = O} had the lowest activities as indicated by pIC50 values of
7.1249, 7.5686, 7.585, and 7.6576, respectively. On the other hand,
only red contour was observed in the electrostatic contour map near
R1 substituent, which indicates that electronegative substituent at the
position would increase the inhibitory activity. This phenomenon
explains the reason why compound 14 (R1 = OMe) displayed low
inhibitory activity (IC50 = 22 nM).
CoMSIA contour map
The COMSIA steric field contour maps are depicted
in Figure 4a. The green contour around R1 means that sterically,
bulky groups are favorable for increasing the inhibitory activity. In
contrast, a yellow contour near the phenyl group means that bulky
group substituent in that position may decrease the inhibitory
activity.
In the CoMSIA electrostatic field (Fig. 4b), the blue
color designates the positively charged groups that are favored for
inhibitory activity, while the red contour denotes the negatively
charged groups, which are favored for improving the inhibitory
activity. CoMSIA hydrophobic contour map is shown in Figure 4c.
The hydrophobic yellow contours can be observed around the
C3 position of R2, which indicates that replacing this position

Figure 3. CoMFA steric (a) and electrostatic (b) contour maps with 2 Å grid spacing. Compound 12 was displayed in the background. In steric and electrostatic fields,
the contribution of green and blue contours, respectively, is 80%, while those of yellow and red, respectively, is 20%.

Figure 4. CoMSIA std*coeff contour maps with compound 12 as a background. (a) Steric fields: contribution of green contours is 80%, while yellow contours are 20%
contribution. (b) Electrostatic fields: blue contours are 80% contribution, while red contours are 20% contribution. (c) Hydrophobic fields: yellow contours are 80%
contribution, while white contours are 20% contribution.

Ruslin et al. / Journal of Applied Pharmaceutical Science 9 (01); 2019: 089-097

094

with hydrophobic groups may increase the activity. In contrast,
the white contour around the C4 position of R2 indicates that
hydrophobic groups are not favored for increasing the activity.
In the CoMSIA HBA (Fig. 5a), the magenta contour
represents that the hydrogen bond acceptor groups are favorable
for increasing the inhibitory activity, while the red contour implies
that the HBA groups would decrease the inhibitory activity. In
the CoMSIA HBD (Fig. 5b), HBD groups are favored in the cyan
contour for increasing the inhibitory activity, while the purple
contour denotes that HBD groups are not preferred. Overall,
electrostatic field contributes the most to the CoMSIA model as
shown in Table 3, which indicates that the electrostatic field is the
most influencing factor to the inhibitory activity of the quinazoline–
phosphoramidate mustard conjugates. This result agrees well with
the CoMFA model, which shows that the electrostatic field is more
important to the inhibitory activity than the steric field (Table 3).
Design for new compound
Based on the proposed 3D CoMFA and CoMSIA models,
new compounds are designed using compound 12 (Comp12) as
a template. All new compounds were minimized and aligned to
the database, and then docked into the active site of EGFR. The

binding affinities (total score) of the newly designed compounds
were higher than that of Comp12. Table 4 depicts the structures of
the newly designed compound using the predicted pIC50 CoMFA
and CoMSIA as well as total scores, while Figure 6 shows
predicted pIC50 values between CoMFA and CoMSIA models.
Molecular docking
To explore the interaction of Comp12, RA1, RA2, RA3,
and RA4 with EGFR, molecular docking using surflex-dock was
applied. The results showed that all Comp12, RA1, RA2, RA3, and
RA4 formed hbond interactions with Met769. In the crystallographic
pose of erlotinib, Met769 was observed in direct hbond. Additional
hbond with Thr766 was established with Comp12, RA1, and RA3,
which was detected in the crystal structure of erlotinib through
water-mediated hbond. Besides, RA1 and RA2 formed hbonds
with Lys721, while Comp12 and RA1 share the same hbond with
Thr830. Figure 7 depicts the docked positions of Comp12, RA1,
RA2, RA3, and RA4 in the binding site of EGFR.
MD simulation and MM-PBSA calculation
MD simulation of 100 ns was performed on each
complex of Comp12, RA1, RA2, RA3, and RA4, with EGFR.

Figure 5. CoMSIA std*coeff. contour maps with compound 12 as a background. (a) H-bond acceptor fields: the magenta contour is 80% contribution, while the red
contour is 20% contribution. (b) H-bond donor fields: the cyan contour is 80% contribution, while purple is 20% contribution.
Table 4. Chemical structures of newly designed compounds and their predicted pIC50 CoMFA and CoMSIA models as
well as total scores.

Compound

Substituent

Predicted pIC50

Total Score

R1

R2

CoMFA

CoMSIA

Comp12

Br

OCH3

9.5269

9.4499

5.7583

RA1

COOH

OCH3

9.5322

9.3532

11.4093

RA2

COCH3

OCH3

9.5451

9.3476

8.4734

RA3

COOCH3

OC2H5

9.3906

9.2980

7.8309

RA4

COOH

OC3H7

9.4528

9.3495

8.1122
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Figure 8a shows the RMSD of the heavy atoms of EGFR during
100 ns. It shows stable conformations of both complexes after 10
ns. To assess the flexibility of amino acid residues during 100 ns,
RMSF plot was measured (Fig. 8b). The results showed that the
two complexes had a similar pattern of residual movements. High
flexibility was observed in the amino and carboxy terminals of the
protein, while the majority of the residues showed rigid flexibility,
which indicated that the ligand binding did not induce a large
change in protein conformation.
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To assess the affinity of each compound to EGFR, MMPBSA calculation was performed (Table 5). It can be inferred from
Table 5 that electrostatic, van der Waals, and non-polar energy of
desolvation were favorable for ligand binding in both complexes.
Whereas, the polar energy of desolvation was not favored,
resulting in unfavorable net electrostatic energies. Interestingly,
the predicted total binding free energy of RA2 (ΔG = −38.32 kcal/
mol) was lower than that of Comp12 (ΔG = −30.48 kcal/mol),
which indicated the good potential of the designed compound.

Figure 6. The pIC50 values between CoMFA and CoMSIA models.

Figure 7. The docked poses of (a) Comp12, (b) RA1, (c) RA2, (d) RA3, and (e) RA4.

Ruslin et al. / Journal of Applied Pharmaceutical Science 9 (01); 2019: 089-097
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a.

b.

Figure 8. (a) RMSD value of each ligand-EGFR complex during 100 ns dynamics runs calculated from heavy atoms of protein for Comp12 (red), RA1 (yellow), RA2
(green), RA3 (blue), and RA4 (purple). (b) RMSF plot of each amino acid residue during 100 ns dynamics simulation for Comp12 (red), RA1 (yellow), RA2 (green),
RA3 (blue), and RA4 (purple).

Table 5. The binding free energy terms (kcal/mol) of each ligand bound to EGFR.
Comp

ΔEELE

ΔEVDW

ΔEPBCAL

ΔEPBSUR

ΔEPBTOT

Comp12

−23.19 ± 9.28

−49.74 ± 5.07

47.43 ± 10.23

−4.98 ± 0.29

−30.48 ± 4.81

RA1

−59.04 ± 8.99

−46.10 ± 3.23

85.57 ± 7.99

−5.09 ± 0.16

−24.66 ± 4.75

RA2

−53.28 ± 10.93

−62.04 ± 3.69

82.89 ± 9.21

−5.89 ± 0.14

−38.32 ± 6.13

RA3

−26.13 ± 10.21

−52.13 ± 3.37

54.65 ± 7.73

−5.33 ± 0.24

−28.93 ± 5.03

RA4

−35.09 ± 9.28

−55.06 ± 4.20

70.18 ± 11.56

−5.70 ± 0.27

−25.67 ± 6.37

CONCLUSION
In the current study, CoMFA and CoMSIA analysis
and molecular docking were performed to explore the structureactivity relationship of novel quinazoline–phosphoramidate
mustard conjugates as an EGFR inhibitor. Both CoMFA and
CoMSIA models were valid with acceptable statistical criteria.
Using CoMFA and CoMSIA contour maps, new compounds
were designed and docked to the binding site of EGFR. The
docked position of the newly designed compounds showed key
interactions with the active site residues of EGFR, which was

stable during 100 ns of MD simulation. The MM-PBSA binding
energy analysis shows that one of the new compounds had higher
affinity than that of the parent compound, thus providing a good
candidate for further drug discovery research.
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